Table 2. Association of sporadic Alzheimer's disease risk with candidate SNPs reported in European descent among Chinese subjects in the discovery set.

Chr	SNP	Position	Gene	Reported risk allelea	Allele frequency		Association testb		Association testc
					SAD	Controls	OR (95% CI)	P value	OR (95% CI)	P value
1	rs6656401	207,692,049	CR1	A	0.028	0.021	1.11(0.51-2.39)	0.800	1.13(0.51-2.52)	0.769
1	rs3818361	207,784,968	CR1	A	0.354	0.378	0.93(0.73-1.19)	0.561	0.92(0.72-1.18)	0.524
2	rs7561528	127,889,637	BIN1	A	0.123	0.151	0.82(0.58-1.16)	0.258	0.87(0.61-1.23)	0.426
2	rs744373	127,894,615	BIN1	G	0.366	0.376	0.97(0.76-1.24)	0.817	0.98(0.76-1.25)	0.848
2	rs35349669	234,068,476	INPP5D	T	0.013	0.011	1.18(0.39-3.52)	0.770	1.17(0.37-3.67)	0.793
5	rs190982	88,223,420	MEF2C	A	0.864	0.849	1.18(0.84-1.68)	0.342	1.27(0.89-1.81)	0.196
6	rs9271192	32,578,530	HLA-DRB5-HLA-DRB1	C	0.144	0.112	1.30(0.91-1.85)	0.144	1.35(0.94-1.94)	0.108
6	rs9349407	47,453,378	CD2AP	C	0.202	0.118	1.95(1.39-2.74)	1.23 × 10−4	2.03(1.43-2.88)	8.38 × 10−5
6	rs11754661	151,207,078	MTHFD1L	A	0.033	0.027	1.19(0.58-2.41)	0.634	1.19(0.57-2.51)	0.647
7	rs2718058	37,841,534	NME8	A	0.754	0.797	0.79(0.60-1.05)	0.103	0.80(0.60-1.07)	0.128
7	rs1476679	100,004,446	ZCWPW1	T	0.708	0.705	1.07(0.83-1.39)	0.589	1.04(0.80-1.35)	0.786
7	rs11767557	143,109,139	EPHA1	T	0.835	0.873	0.74(0.53-1.03)	0.072	0.76(0.54-1.06)	0.109
7	rs11771145	143,110,762	EPHA1	G	0.507	0.463	1.12(0.88-1.42)	0.357	1.03(0.81-1.32)	0.803
8	rs28834970	27,195,121	PTK2B	C	0.276	0.302	0.88(0.67-1.14)	0.332	0.88(0.67-1.16)	0.367
8	rs11136000	27,464,519	CLU	C	0.832	0.806	1.18(0.87-1.60)	0.284	1.17(0.86-1.60)	0.319
8	rs569214	27,487,790	CLU	G	0.489	0.505	0.97(0.76-1.24)	0.803	0.98(0.76-1.27)	0.895
11	rs983392	59,923,508	MS4A6A	A	0.959	0.972	0.77(0.41-1.43)	0.404	0.68(0.36-1.27)	0.225
11	rs610932	59,939,307	MS4A6A	G	0.667	0.646	1.11(0.87-1.43)	0.398	1.09(0.84-1.42)	0.496
11	rs4938933	60,034,429	MS4A4A	T	0.754	0.726	1.15(0.88-1.51)	0.305	1.15(0.86-1.52)	0.345
11	rs2373115	78,091,150	GAB2	C	0.580	0.594	0.95(0.75-1.20)	0.648	0.93(0.73-1.19)	0.581
11	rs17817600	85,677,471	PICALM	G	0.037	0.043	0.85(0.45-1.59)	0.607	0.67(0.35-1.30)	0.238
11	rs3851179	85,868,640	PICALM	C	0.635	0.598	1.17(0.92-1.49)	0.194	1.19(0.93-1.52)	0.177
11	rs11218343	121,435,587	SORL1	T	0.750	0.669	1.60(1.22-2.11)	8.32 × 10−4	1.57(1.18-2.09)	0.002
14	rs17125944	53,400,629	FERMT2	C	0.263	0.218	1.32(1.00-1.75)	0.048	1.35(1.02-1.81)	0.040
14	rs10498633	92,926,952	SLC24A4	G	0.884	0.884	1.04(0.72-1.50)	0.838	1.10(0.76-1.61)	0.606
19	rs3764650	1,046,520	ABCA7	G	0.321	0.276	1.25(0.96-1.61)	0.097	1.26(0.96-1.64)	0.093
19	rs6859	45,382,034	PVRL2	A	0.403	0.307	1.51(1.18-1.94)	0.001	1.22(0.93-1.59)	0.149
19	rs157580	45,395,266	TOMM40	A	0.531	0.473	1.29(1.02-1.65)	0.036	1.04(0.80-1.35)	0.769
19	rs2075650	45,395,619	TOMM40	G	0.236	0.084	3.19(2.25-4.52)	7.87 × 10−11	2.50(1.60-3.91)	6.16 × 10−5
19	rs3865444	51,727,962	CD33	C	0.838	0.840	0.97(0.70-1.36)	0.878	1.03(0.73-1.45)	0.888

Abbreviation: SAD, sporadic Alzheimer's disease; Chr, chromosome; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

^aRisk allele reported in European population.

^bAssociation test was adjusted for sex, age (age at onset for SAD patients and age at examination for control subjects).

^cAssociation test was adjusted for sex, age (age at onset for SAD patients and age at examination for control subjects) and APOE ε4 status (0 or 1).